| 臺大學術典藏 |
2020-08-13T05:24:19Z |
Case report
|
Lin C.-C.; JANN-YUAN WANG; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chih-Hsin Yang;Cheng A.-L;Keng H.-Y;Hsu C.-H;Pu Y.-S;Lin C.-C; Lin C.-C; Pu Y.-S; Hsu C.-H; Keng H.-Y; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Pu Y.-S.;Cheng A.-L;Tsai T.-C;Chen J;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Chen J; Tsai T.-C; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells
|
Hour T.-C.;Lin S.-R;Guan J.-Y;Chia-Chi Lin;Huang C.-Y;Liu G.-Y;Wang C.-W;Hsieh M.-W;Pu Y.-S; Pu Y.-S; Hsieh M.-W; Wang C.-W; Liu G.-Y; Huang C.-Y; Chia-Chi Lin; Guan J.-Y; Lin S.-R; Hour T.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer
|
Hour T.-C; Pu Y.-S; Chia-Chi Lin; Huang S.-W; Chen J; Chiu A.W; Chen C.-J; Huang C.-Y. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide
|
Pu Y.-S.;Lee J.-M;Guan J.-Y;Chen J;Chia-Chi Lin;Huang C.-Y;Hour T.-C; Hour T.-C; Huang C.-Y; Chia-Chi Lin; Chen J; Guan J.-Y; Lee J.-M; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Changing trends of prostate cancer in Asia
|
Chen J.;Huang K.-H;Huang C.-Y;Chia-Chi Lin;Chiang H.-S;Pu Y.-S; Pu Y.-S; Chiang H.-S; Chia-Chi Lin; Huang C.-Y; Huang K.-H; Chen J. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Pu Y.-S.;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Pu Y.-S.;Vogelzang N.J;Chen J;Cheng A.-L;Huang C.-Y;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Cheng A.-L; Chen J; Vogelzang N.J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Keng H.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Cheng A.-L; Vogelzang N.J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Systemic therapy for metastatic urothelial carcinoma
|
Chia-Chi Lin; Hsu C.-H; Pu Y.-S; Vogelzang N.J. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Chia-Chi Lin; Hsu C.-H; Hour T.-C; Cheng A.-L; Huang C.-Y; Huang K.-H; Chen J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:31Z |
Down-regulated expression of RhoA in human conventional renal cell carcinoma
|
Hour T.-C.;Wu W.-J;Chia-Chi Lin;Shun C.-T;Kang W.-Y;Huang C.-Y;Kuo Y.-Z;Liu G.-Y;Wang C.-W;Pu Y.-S; Pu Y.-S; Wang C.-W; Liu G.-Y; Kuo Y.-Z; Huang C.-Y; Kang W.-Y; Shun C.-T; Chia-Chi Lin; Wu W.-J; Hour T.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chia-Chi Lin; Pu Y.-S; Hsu C.-H; Keng H.-Y; Cheng A.-L; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:29Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Huang C.-Y; Cheng J.C; Chia-Chi Lin; Hsu C.-H; Tsai Y.-C; Hsu F.-M; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:24Z |
Reply to S. Vale
|
Chia-Chi Lin; Wang J.-Y; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y; Cheng J.C.-H; Huang C.-Y; Tsai Y.-C; Chia-Chi Lin; Hsu C.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T02:45:40Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C; Hsu C.-H; Cheng J.C; Huang C.-Y; Tsai Y.-C; Feng-Ming Hsu; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T02:45:33Z |
Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma
|
Feng-Ming Hsu; Hou W.-H; Huang C.-Y; Wang C.-C; Tsai C.-L; Tsai Y.-C; Yu H.-J; Pu Y.-S; Cheng J.C.-H. |
| 臺大學術典藏 |
2020-05-19T02:02:44Z |
Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis
|
Yu-Kang Tu;Pu Y.-S.;Chien K.-L.;Yeh Y.-C.;Shih M.-C.;Tseng C.-S.;Tsai C.-Y.;Huang S.-W.; Huang S.-W.; Tsai C.-Y.; Tseng C.-S.; Shih M.-C.; Yeh Y.-C.; Chien K.-L.; Pu Y.-S.; YU-KANG TU |
| 臺大學術典藏 |
2020-04-28T07:25:40Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.;Chih-Hung Hsu;Chen J.;Tsai T.-C.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; CHIH-HUNG HSU; Chen J.; Tsai T.-C.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-28T07:25:40Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Chih-Hung Hsu;Chen J.;Wu C.-Y.;Cheng A.-L.;Pu Y.-S.; CHIH-HUNG HSU; Chen J.; Wu C.-Y.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-28T07:25:39Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y.; Lin B.-R.; Lin J.-T.; Ko J.-Y.; She T.-S.; Ho Y.-F.; CHIH-HUNG HSU; Lin J.-K.; Hsu M.-M.; Chen A.-L.; Chen A.-L.;Chih-Hung Hsu;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y. |
